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Prognostic factors in a T3 bladder cancer trial
Co-operative Urological Cancer Group*
Summary Information on primary tumour size, status of the pelvic lymph nodes, histological type and
macroscopic tumour appearance, as well as age and sex, was available at presentation for 394 patients in the
Co-operative Urological Cancer Group's prospective randomised trial for T3 cancer of the urinary bladder.
An apparently significant prognostic effect of age and sex was shown to be entirely consistent with the effect
of natural mortality. Primary tumour size was found to be the single most powerful prognostic factor
(P=0.002), followed by nodal status (P=0.02). These factors do not act independently. Multivariate analysis
showed that 75% of the effect of all the six variables and their first order interactions could be explained by a
single prognostic grouping based on tumour size and nodal status only. Three levels for this grouping are
proposed: node-negative small tumour, node-negative moderate tumour and either node-positive or large
tumour. The 3-year survival probabilities for the three prognostic groups were 85.7% (95% CI 57.2 and
96.4%), 60.3% (48.0 and 71.5%) and 33.3% (23.5 and 44.8%) respectively.
Between 1978 and 1987, 400 patients with T3 MO bladder
tumours were entered into a multicentre randomised
prospective trial of neo-adjuvant and maintenance chemo-
therapy. Details of the trial, the treatment arms, and the
preliminary results are published elsewhere (Co-operative
Urological Cancer Group, 1988). There was no difference in
survival between the two arms of the trial. The notification
(or entry) form for the trial contained information on
potential prognostic variables and in this paper we examine
these factors in detail. We also wished to investigate the
effect on survival of allowing for general population mor-
tality in this elderly group of patients.
Patients and methods
This analysis is based on 394 patients (for whom we had
notification forms) presenting with T3 MO bladder cancer
and randomised between June 1978 and January 1987 in a
multicentre randomised trial organised by the Co-operative
Urological Cancer Group. Of these patients, 319 were
treated by radical radiotherapy, 75 by preoperative radio-
therapy and radical cystectomy and 197 patients had adju-
vant methotrexate as well as local treatment as detailed in
the trial report (Sheare et al., 1988). Overall, 260 patients
have died and 134 are still alive or lost to follow-up. Among
the latter group eight had no follow-up time and so they did
not contribute to the analysis.
The following variables with values available at presen-
tation were examined: sex, age, primary tumour size, meta-
stases to local lymph nodes, macroscopic tumour appearance
and histological type. Size was classified according to the
maximum diameter of the primary tumour measured at
cystoscopy as small (less than 2.5cm), moderate (2.5cm or
more but less than 4.5cm) and large (4.5cm or more). Size
measurements were available for 370 patients. Macroscopic
tumour appearance was categorised as papillary or solid.
The former category included papillary tumours only, while
combinations of papillary and solid tumours were assigned
to the 'solid' category. Information on macroscopic tumour
appearance, histological type and status of lymph nodes was
available for 385, 340 and 169 patients respectively.
Product-limit estimates (Kaplan & Meier, 1958) were used
for survival curves, and 95% confidence intervals (CI) for
survival probabilities calculated. A proportional hazard
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model (Cox, 1972) was assumed. Here, the term 'hazard'
refers mainly to the mortality rate. The only exception is
when adjustment was made for natural mortality in evalu-
ating the prognostic value of age and sex when a propor-
tional 'excess mortality' model was used, i.e. mortality in
excess of that expected in a group of the same age and sex
composition in the general population. The latter was esti-
mated using the 1984 rates for England and Wales (OPCS,
1985). The long duration of the trial and the relatively old
age of the patients in this series (median age 69 years)
prompted us to take natural mortality into consideration.
This adjustment was not made when the prognostic effects of
factors other than age and sex were evaluated, as all the
analyses involving non-demographic factors were adjusted
for age and sex.
Results
The overall median survival time was 22 months. Estimates
of the 3-year and 5-year survival probabilities were 38%
(95% CI 33 and 43%) and 27% (95% CI 22 and 33%)
respectively. The effect on mortality of age and sex (each
adjusted for the other) is shown in Table I. The weak
evidence of a poorer prognosis for men as compared to
women (X2 =3.04, d.f. =1, P=0.08) diminishes when natural
mortality is taken into account, and completely disappears
when a further adjustment is made for nodal status
(X2 =0.80, d.f. = 1, P =0.37). The significant positive trend in
mortality rate with age is explained by the variation in
natural mortality between the age groups (X2 =4.88, d.f. =1)
for trend in mortality diminishes to x2=0.5 for trend in
excess mortality, i.e. after allowing for natural mortality.
Furthermore, a formal analysis of bladder-cancer specific
Table I Prognostic value of sex and age
Factors Number of Mortality Excess rate
and levels patients rate ratio ratioa
Sex
Women 87 1.0 1.0
Men 299 1.3 1.2
Age (years)
< 59 66 1.0 1.0
60-64 78 1.4 1.3
65-69 80 1.3 1.2
70-74 100 1.4 1.3
75 62 1.6* 1.2
trend X2=4.88 trend x2=0.5
P=0.03 P=0.48
*P<0.05.
aRatio of death rates in excess of that expected from natural
mortality.
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mortality revealed no significant effect of age (2 =1.97,
d.f. = 1, P=0.16) or sex (x2 = 1.18, P=0.27). Thus there is no
evidence of any intrinsic prognostic effect of these two
demographic factors.
The performances of the other variables considered separ-
ately (but each adjusted for age and sex) are shown in Table
II. The factor with the greatest predictive power (as meas-
ured by the value of X2) was primary tumour size (trend
x2= 9.94, d.f. = 1, P=0.002). This is illustrated graphically in
Figure la. Median survival times for small, moderate and
Table II Prognostic value of non-demographic factors
Number of
Factors and levels patients Rate ratioa
Tumour size
Small 42 1.0
Moderate 165 1.5
Large 155 1.9**
Trend x2=9.94
P=0.002
Nodal status
Node-negative 129 1.0
Node-positive 40 1.7*
Tumour appearance
Papillary 37 1.0
Solid 340 1.3
Histology
Transitional cell 325 1.0
Squamous cell 11 1.7
*P<0.05; **P<0.01.
aAdjusted for age and sex.
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large tumours were 36, 24 and 15 months respectively. The
corresponding 5-year survival probabilities were 34, 28 and
23% respectively.
The second most predictive variable was nodal status
(X2=5.41, d.f.=1, P=0.02). The estimated median survival
time and 5-year survival probability for node-positive
patients were 14 months and 18% compared to 30 months
and 33% for node-negative patients. Figure lb gives the
survival curves for the two groups.
The data do not provide evidence of a significant effect of
tumour appearance and cell type on prognosis. The lack of
evidence for the latter variable may be due to the small
number of patients with squamous cell carcinoma.
Investigation of the joint prognostic effect of the above
variables revealed a very significant interaction between
tumour size and nodal status (X2=10.50, d.f.=2, P=0.005).
Table III gives the mortality rate ratios for the combinations
of the levels of these two factors. The rate ratios are relative
to the node-negative small tumour category. The positive
and highly significant trend in mortality rate with tumour
size (x2 = 12.70, d.f. = 1, P<0.0005) when there is no involve-
ment of the local lymph nodes is contrasted with an
apparent negative trend among the node-positive patients.
However, this negative trend in the latter group is not
statistically significant (X2=2.42, d.f.= 1, P>0.1). Further
analysis of this interaction showed that more than 90% of
its effect (as measured by x2 =10.50, d.f. =2) was due to the
difference in the prognostic effect of nodal status within
patients with large tumours on the one hand, and small or
moderate tumours on the other hand. Furthermore, there
was no significant difference in mortality rate between node-
positive and node-negative patients with large tumours. This
suggested that primary tumour size and nodal status might
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Figure 1 (a) Survival by size of primary tumour: <2.5cm max. diameter; ------ 2.5-4.4cm max. diameter; ......
>4.5cm max. diameter. (b) Survival by nodal status: node-negative; ------ node-positive. (c) Survival by tumour
appearance: solid; ------ papillary. (d) Survival by histological type: squamous cell; ------ transitional cell.
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Table III Death rate ratios according to tumour size and
lymph nodes involvement
Tumour size
Nodal status <2.5cm 2.5-3.4cm .4.5 cm
Node-negative 1.0 2.1 3.9**
Node-positive 5.5* 5.4** 2.7
*P<0.05; **P<0.01.
Table IV Mortality according to prognostic group
Mortality
Groupa No. patients rate ratiob
Group 1
Group 2
Group 3
14
66
82
1.0
2.1
4.0**
**P<O0.1.
aSee text for definition; bTrend x2 =16.4, d.f. = 1,
P<O.O001.
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Figure 2 Survival by prognostic group: group 1, node-
negative and small tumour; ------ group 2, node-negative and
moderate tumour; .*-- group 3, node-positive and/or large
tumour.
be combined into the following prognostic groupings: (1)
node-negative and small tumour; (2) node-negative and
moderate tumour; (3) node-positive or large tumour. The
mortality rate ratios for these groups are given in Table IV
and the corresponding survival curves in Figure 2. The
mortality rate is approximately doubled from one level to
the next. The predictive power is measured by the highly
significant trend (X2 = 16.40, d.f. = 1, P<0.0001).
Discussion
Conflicting results have been reported on the prognostic
effect of age and gender (Bloom et al., 1982; Narayana et al.,
1983; Pryor, 1973; Blandy et al., 1980). In terms of (unad-
justed) survival, the present series showed a significant
negative trend in survival rate with age (younger patients
faring better than older ones) and weak evidence of poorer
prognosis for men as compared to women. However, after
correcting for natural mortality, the adjusted rates showed
no significant dependence on age or sex. The material
influence of natural mortality is due to the old age of the
patients entered and the length of the follow-up period. Our
findings highlight the need for taking natural mortality into
account when investigating prognostic factors in trials of
moderate length with elderly patients. A simple way of
achieving this is to adjust the analysis for age and sex even if
the influence of age and sex is not statistically significant,
Alternatively, the analysis could be based on mortality
specific to the disease under study. This can be more efficient
if the disease specific mortality is much lower than natural
mortality from all causes, but it is of less value when the
recorded cause of death is not very accurate, as is sometimes
the case, particularly in elderly patients and in situations
when death from other causes may be indirectly related to
the study disease or its treatment. In the present series 202
patients have died from bladder cancer, seven from post-
operative complications and 51 from other causes. The
number of deaths from causes other than bladder cancer or
operative mortality was significantly higher than the total
number expected (36.5) from all cause natural mortality
(P=0.01), suggesting, as expected, that these deaths were
bladder cancer related.
Invasive papillary carcinomas are reported to be more
radiosensitive, less likely to spread to the pelvic nodes and
confer more favourable prognosis than invasive solid
tumours (Slack & Prout, 1980; Heney et al., 1983). In the
present series, nodal status was recorded for 17 patients with
papillary tumours, of whom five (23%) were node positive.
The corresponding figure for 109 patients with solid tumours
and ascertained nodal status was 34 (24%), providing no
evidence of a difference in the tendency to metastasise
locally. Similarly there was no overall survival difference in
the two groups (see Figure 1c).
Although the mortality rate in the few patients with
squamous cell tumours was 70% higher than in those with
transitional cell tumours, there is little evidence of a real
survival difference Figure Id). This may be due to the small
number of patients in the former group (11 patients with
squamous cell carcinoma versus 325 with transitional cell
carcinoma).
The poor performance of large primary tumours has been
reported by Narayana et al. (1983) and, at least within one
treatment arm, by Bloom et al. (1982). We found that the
presentation size of the primary tumour was the single most
important prognostic factor. The mortality rates for small,
moderate and large tumours were, on average, in the ratios
1:1.5:2.
Metastasis to the regional lymph nodes is well recognised
as an indicator of poor prognosis. Smith & Whitmore (1981)
reported 7% 5-year survival in 134 node-positive patients.
Heney et al. (1983) found 3% 5-year survival in 23 node-
positive patients compared to 41% in 59 node-negative
patients, while Bloom et al. (1982) reported 18 and 53%
(corrected) 5-year survival for the two groups. Our data
confirm these findings. We found nodal status to be the
second most important prognostic variable. On average,
node-positive patients experienced a 70% higher mortality
rate than node-negative patients.
Primary tumour size and nodal status do not appear to
act independently. We found a very significant interaction
between the effects of these two variables on prognosis. A
highly significant positive trend in mortality with tumour
size in node-negative patients is in contrast to a negative
though not quite significant trend in node-positive patients.
The fact that the latter is not statistically significant suggests
that the nature of this interaction is likely to be quantitative
rather than qualitative, where by a 'quantitative interaction'
between two factors A and B, we mean a situation where
there is variation in magnitude, but not in direction, of the
effect of A among the levels defined by B and vice-versa.
The situation where there is reversal of direction is termed
qualitative or cross-over interaction. One possible expla-
nation for the lack of any difference in mortality rate
between node-positive and node-negative patients with large
tumours is that involvement of the lymph nodes tends to be
underdetected in general, and that large tumours are much
more likely to have metastasised to the local lymph nodes
than small or moderate tumours.
Based on the above findings, we propose the following
prognostic groupings: (1) node-negative and small primary
tumour; (2) node-negative and moderate primary tumour; (3)444 CO-OPERATIVE UROLOGICAL CANCER GROUP
node-positive or large primary tumour. This grouping
accounted for more than 75% of all variation in survival
accounted for by all the six variables and their first order
interactions. However, the true performance of this grouping
can only be judged on independent data.
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